New Therapeutic Target for Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Monoclonal Antibodies.
New Therapeutic Target for Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Monoclonal Antibodies.
Not yet recruiting · NCT07110662 · Registry updated 2025-08-07Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| New Therapeutic Target for Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Monoclonal Antibodies. | Chemically-Induced Disorders, Drug Eruptions, Drug-Related Side Effects and Adverse Reactions, Erythema, Hypersensitivity, Delayed, Skin and Connective Tissue Diseases, Stevens-Johnson syndrome, Stomatognathic Diseases, dermatitis, drug allergy, erythema multiforme, immune system disorder, mouth disorder, skin disorder, stomatitis, vesiculobullous skin disease | Not yet recruiting | Phase 1 / Phase 2 | 2025-08-07 | NCT07110662 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Hospices Civils de Lyon | 429 |
| INSERM U1111 | 1 |
| Janssen-Cilag Ltd. | 14 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Reference Center for Toxic, Toxin and Toxidermal Bullous Dermatoses - E. Herriot Hospital | Lyon | France | 1 |